Genmab (NASDAQ:GMAB) today reported robust first-quarter 2025 worldwide net trade sales for DARZALEX (daratumumab), as reported by its licensee, Johnson & Johnson (NYSE:JNJ).
The total global sales reached USD 3,237 million for the period ending March 31, 2025.
According to Genmab's announcement, the U.S. market accounted for USD 1,829 million in net trade sales, while the rest of the world contributed USD 1,409 million.
These figures include sales of both the intravenous formulation of DARZALEX and the subcutaneous (SC) product, known as DARZALEX FASPRO® in the United States (daratumumab and hyaluronidase-fihj).
Genmab receives royalties on the global net sales of DARZALEX under an exclusive worldwide license granted to J&J for the development, manufacturing, and commercialization of the daratumumab-based therapy.
The strong sales figures indicate continued global demand for the multiple myeloma treatment.